The short version of BPC-157 fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-12-01. Anything still debated is marked as such rather than presented as settled.
Once dissolved, the material is considerably less stable than the dry solid. Aqueous solutions are usually kept cold and used within a short window, and neutral or mildly acidic buffers are preferred over strongly alkaline conditions. Freeze-thaw cycles promote aggregation and loss of material to container surfaces, so dividing a batch into single-use aliquots is standard. Adsorption to plastic and glass can lower the measured concentration, meaning solution strength may need rechecking before an experiment.
Identity and purity are established with complementary methods rather than one test. Reverse-phase high-performance liquid chromatography separates the main peak from deletion sequences and oxidized variants, and its area percentage is the usual purity figure. Mass spectrometry confirms the expected molecular mass and can flag truncations or modifications that chromatography alone might miss. Amino acid analysis and peptide mapping add sequence-level confirmation, while residual counter-ion and water content are measured separately.
Common synonyms in catalogs include pentadecapeptide BPC 157, BPC157, and the full sequence name. A CAS registry number in the 137525-51-0 range is frequently listed, though the assignment should be verified against the supplier certificate of analysis. The name itself is not a pharmacopoeial designation, and there is no standardized international nonproprietary name. Distinguishing genuine material from related fragments generally requires mass spectrometry, since several truncated sequences share similar chromatographic behavior.
BPC-157 is a synthetic pentadecapeptide whose sequence is commonly given as Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is described in the literature as a fragment of a larger protein found in human gastric juice, referred to as body protection compound. The peptide was first characterized in the early 1990s by a research group in Zagreb, Croatia. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Supplied material is typically a lyophilized white to off-white powder. The peptide is freely soluble in water and in common aqueous buffers, which allows it to be handled as a stock solution. Because the sequence contains no cysteine, disulfide cross-linking is not a route of degradation. The absence of aromatic residues means ultraviolet absorbance at 280 nm is minimal, so quantification usually relies on peptide bond absorbance near 214 nm or on amino acid analysis.
| Property | Value | Notes |
|---|---|---|
| Dry powder storage | -20 °C or below | Desiccated and protected from light |
| Solution storage | 2-8 °C, short term | Aliquot to avoid freeze-thaw cycling |
| Reconstitution solvent | Water or buffered saline | Near-neutral pH is generally preferred |
| Identity confirmation | Mass spectrometry | Matches expected monoisotopic mass |
| Purity assessment | Reverse-phase HPLC | Reported as main-peak area percentage |
Terminology in the literature is not fully standardised. Papers and product listings use BPC-157, BPC 157, and the longer phrase stable gastric pentadecapeptide BPC 157 interchangeably, and synonyms such as bepecin or PL 14736 appear in older or company-linked publications. Purity claims and reported masses can also differ between sources because peptide preparations may include counterions, residual solvents, or bound water. This variability complicates direct comparison of results across studies and makes the exact identity and grade of a given sample worth verifying. Discussions of the compound should therefore specify the source, salt form, and stated purity where those are known.
BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Analytical results depend on the column, gradient, and detector wavelength chosen by the laboratory, so purity values from different sources are not always directly comparable. Water content, counterion form, and residual trifluoroacetate affect both mass and purity calculations. Microbiological and endotoxin testing are separate from chemical purity and are not covered by a standard chromatographic run. Buyers evaluating a material typically request the full method description rather than a single purity figure.
Lyophilized peptide powder is generally stored at minus twenty degrees Celsius or lower and kept away from light and moisture. Under these conditions degradation is slow, and sealed vials remain stable for extended periods. Once dissolved, the material is less stable, particularly in aqueous buffers near neutral pH, where hydrolysis and oxidation proceed faster. Solutions are usually kept cold and used within days to weeks. Repeated freeze-thaw cycles are avoided because they encourage aggregation.
Identity and purity are established using reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities and yields a percentage purity. Mass spectrometry, typically with electrospray ionization, confirms the molecular mass against the expected value. Amino acid analysis or peptide mapping provides additional sequence confirmation. These methods are complementary, since chromatography measures how much material is present while mass spectrometry verifies what that material is. A certificate of analysis normally reports both.
The major practical problem of the entire proposal, however, was collecting the radioactive debris dispersed by the powerful blast. Aircraft filters adsorbed only about 4×10−14 of the total amount and collection of tons of corals at Enewetak Atoll increased this fraction by only two orders of magnitude. Extraction of about 500 kilograms of underground rocks 60 days after the Hutch explosion recovered only about 10−7 of the total charge. The amount of transuranium elements in this 500-kg batch was only 30 times higher than in a 0.4 kg rock picked up 7 days after the test. This observation demonstrated the highly nonlinear dependence of the transuranium elements yield on the amount of retrieved radioactive rock. In order to accelerate sample collection after the explosion, shafts were drilled at the site not after but before the test, so that the explosion would expel radioactive material from the epicenter, through the shafts, to collecting volumes near the surface. This method was tried in the Anacostia and Kennebec tests and instantly provided hundreds of kilograms of material, but with actinide concentrations 3 times lower than in samples obtained after drilling; whereas such a method could have been efficient in scientific studies of short-lived isotopes, it could not improve the overall collection efficiency of the produced actinides.
== Drug targeting == Certain antibiotics, such as tetracyclines, prevent the aminoacyl-tRNA from binding to the ribosomal subunit in prokaryotes. It is understood that tetracyclines inhibit the attachment of aa-tRNA within the acceptor (A) site of prokaryotic ribosomes during translation. Tetracyclines are considered broad-spectrum antibiotic agents; these drugs exhibit capabilities of inhibiting the growth of both gram-positive and gram-negative bacteria, as well as other atypical microorganisms. Furthermore, the TetM protein (P21598) is found to allow aminoacyl-tRNA molecules to bind to the ribosomal acceptor site, despite being concentrated with tetracyclines that would typically inhibit such actions. The TetM protein is regarded as a ribosomal protection protein, exhibiting GTPase activity that is dependent upon ribosomes. Research has demonstrated that in the presence of TetM proteins, tetracyclines are released from ribosomes. Thus, this allows for aa-tRNA binding to the A site of ribosomes, as it is no longer precluded by tetracycline molecules. TetO is 75% similar to TetM, and both have some 45% similarity with EF-G. The structure of TetM in complex with E. coli ribosome has been resolved.
This myth spread because it was not then uncommon for black people to be refused treatment because there were not enough "Negro beds" available or because the nearest hospital only serviced white people.
=== Halides === Erbium(III) fluoride is a pinkish powder that can be produced by reacting erbium(III) nitrate and ammonium fluoride. It can be used to make infrared light-transmitting materials and up-converting luminescent materials, and is an intermediate in the production of erbium metal prior to its reduction with calcium. Erbium(III) chloride is a violet compounds that can be formed by first heating erbium(III) oxide and ammonium chloride to produce the ammonium salt of the pentachloride ((NH4)2ErCl5) then heating it in a vacuum at 350-400 °C. It forms crystals of the aluminium chloride type, with monoclinic crystals and the point group C2/m. Erbium(III) chloride hexahydrate also forms monoclinic crystals with the point group of P2/n (P2/c) - C42h. In this compound, erbium is octa-coordinated to form [Er(H2O)6Cl2]+ ions with the isolated Cl− completing the structure. Erbium(III) bromide is a violet solid. It is used, like other metal bromide compounds, in water treatment, chemical analysis and for certain crystal growth applications. Erbium(III) iodide is a slightly pink compound that is insoluble in water. It can be prepared by directly reacting erbium with iodine.
At the beginning of sleep, a patient is in light sleep with no loss of tone in the throat muscles. Airflow is laminar and soundless. As the upper airway collapses, the obstruction becomes increasingly apparent with the initiation of noisy breathing as air turbulence increases, followed by gradually louder snoring as a Venturi effect forms through the ever-narrowing air passage. The patient's blood-oxygen saturation gradually falls until sleep noise stops, signifying total airway obstruction. This may last for several minutes. Eventually, the patient must at least partially awaken from deep sleep into light sleep, automatically regaining general muscle tone. This switch from deep to light to deep sleep can be recorded using ECT monitors. In light sleep, muscle tone is near normal, the airway spontaneously opens, normal noiseless breathing resumes, and blood oxygen saturation rises. Eventually, the patient reenters deep sleep, upper airway tone is lost, the patient enters the various levels of noisy breathing, and airway blockage returns. The cycle of muscle tone loss and restoration, coinciding with periods of deep and light sleep, repeats throughout the patient's sleep period. The number of apnoea and hypopnoea episodes during any given hour is counted and given a score. If a patient has an average of five or more episodes per hour, mild OSA may be confirmed. An average of 30 or more episodes per hour indicates severe OSA.
Sources: en.wikipedia.org
The ocular complications of MFS can often be treated with surgery. Ectopia lentis can be treated, as artificial lenses can be surgically implanted. In addition, surgery can address glaucoma, retinal detachment or tears, and cataracts. Treatment of a spontaneous pneumothorax is dependent on the volume of air in the pleural space and the natural progression of the individual's condition. A small pneumothorax might resolve without active treatment in one to two weeks. Recurrent pneumothoraces might require chest surgery. Moderately sized pneumothoraces might need chest drain management for several days in a hospital. Large pneumothoraces are likely to be medical emergencies requiring emergency decompression. As an alternative approach, custom-built supports for the aortic root are also being used. As of 2020 this procedure has been used in over 300 people with the first case occurring in 2004.
== Flow types == Microfluidic flows need only be constrained by geometrical length scale – the modalities and methods used to achieve such a geometrical constraint are highly dependent on the targeted application. Traditionally, microfluidic flows have been generated inside closed channels with the channel cross section being in the order of 10 μm x 10 μm. Each of these methods has its own associated techniques to maintain robust fluid flow which have matured over several years.
Penis or pizzle is a type of offal. In many cultures, it is a taboo food. Penis is eaten in some cultures or traditional medicine systems as a purported health food: it may be seen as an aphrodisiac, a cure for sexual dysfunction, a hangover cure, and more. Penis is often paired with testicles as food.
Innovations continued through the Middle Ages with the introduction of silk production (in Asia and later Europe), the horse collar, and horseshoes. Simple machines (such as the lever, the screw, and the pulley) were combined into more complicated tools, such as the wheelbarrow, windmills, and clocks. A system of universities developed and spread scientific ideas and practices, including Oxford and Cambridge. The Renaissance era produced many innovations, including the introduction of the movable type printing press to Europe, which facilitated the communication of knowledge. Technology became increasingly influenced by science, beginning a cycle of mutual advancement.
These churches provide a space for worship and community support for those who have left the Druze faith. Prominent converts from the Druze faith to Christianity include: Mohamed Alí Seineldín, Nada Nadim Prouty, Selwa Carmen Showker "Lucky" Roosevelt, and others.
Sources: en.wikipedia.org
=== Rules for generic biologics === Since the 1990s, many successful new drugs for the treatment of cancer, autoimmune diseases, and other conditions have been protein-based biotechnology drugs, regulated by the Center for Biologics Evaluation and Research. Many of these drugs are extremely expensive; for example, the anti-cancer drug Avastin costs $55,000 for a year of treatment, while the enzyme replacement therapy drug Cerezyme costs $200,000 per year, and must be taken by Gaucher's disease patients for life. Biotechnology drugs do not have the simple, readily verifiable chemical structures of conventional drugs, and are produced through complex, often proprietary, techniques, such as transgenic mammalian cell cultures. Because of these complexities, the 1984 Hatch-Waxman Act did not include biologics in the Abbreviated New Drug Application (ANDA) process. This precluded the possibility of generic drug competition for biotechnology drugs. In February 2007, identical bills were introduced into the House to create an ANDA process for the approval of generic biologics, but were not passed.
Styrene-butane co-polymers do not break at this point, but begin to flow, solidify to tensile strength and only break at much higher elongation. With a high proportion of polybutadiene, the effect of the two phases is reversed. Styrene-butadiene rubber behaves like an elastomer but can be processed like a thermoplastic.
=== Special populations === Patients already suffering from debilitation are at a much higher risk of respiratory depression. Non-opioid analgesics should be considered in this population. Elderly patients are much more sensitive to adverse effects such as falls, cognitive impairment and constipation, and should be monitored for such. Decreased renal function associated with aging leads to decreased clearance of the drug, resulting in narrow therapeutic windows and increasing the danger of overdose. If oxymorphone is absolutely indicated, smaller initial doses should be started for this population. There is a risk of neonatal withdrawal symptom in the newborn if pregnant women take oxymorphone for a prolonged period. Oxymorphone crosses the placenta and holds risk of birth defects, poor fetal growth, stillbirth, and preterm delivery. The children of mothers who are physically dependent on oxymorphone have a higher risk of similar dependence. Due to these severe risks, oxymorphone is highly discouraged among this population. The amount of transfer of oxymorphone into the breast milk is not known and women are cautioned to weigh the risks and benefits before breastfeeding while on this medication.
Although there was no patent on the compound, the provisions of the Waxman-Hatch Act gave Bristol-Myers Squibb five years exclusive marketing rights. In 1990, BMS applied to trademark the name taxol as Taxol(R). This was controversially approved in 1992. At the same time, paclitaxel replaced taxol as the generic (INN) name of the compound. Critics, including the journal Nature, argued the name taxol had been used for more than two decades and in more than 600 scientific articles and suggested the trademark should not have been awarded and the BMS should renounce its rights to it. BMS argued changing the name would cause confusion among oncologists and possibly endanger the health of patients. BMS has continued to defend its rights to the name in the courts. BMS has also been criticized for misrepresentation by Goodman and Walsh, who quote from a company report saying "It was not until 1971 that ... testing ... enabled the isolation of paclitaxel, initially described as 'compound 17". This quote is, strictly speaking, accurate: the objection seems to be that this misleadingly neglects to explain that it was the scientist doing the isolation who named the compound taxol and it was not referred to in any other way for more than twenty years. Annual sales peaked in 2000 (the same year that several of BMS's Taxol patents were invalidated via legal challenge from generic manufacturers), reaching US$1.6 billion; paclitaxel became available in generic form in 2000.
A cessation of hostilities beginning on 16 April 2026 at 17:00 EST for an initial period of ten days, intended to enable negotiations toward a permanent agreement. The possibility of extending the ceasefire by mutual agreement if progress is made in negotiations and Lebanon demonstrates effective sovereignty. Israel retains the right to act in self-defense against imminent or ongoing threats, while refraining from offensive military operations in Lebanon. Lebanon, with international support, is to take steps to prevent Hezbollah and other non-state armed groups from carrying out attacks against Israel. Recognition of the Lebanese state's security forces as solely responsible for national sovereignty and defense. A request for the United States to facilitate further direct negotiations, including on border demarcation and a comprehensive peace agreement. Hezbollah was not a formal signatory to the agreement, despite being a principal party in the fighting.
Sources: en.wikipedia.org
Low temperature slows the chemical reactions, such as oxidation and hydrolysis, that break down a peptide chain. Water and oxygen are the main drivers of degradation, so a cold and dry environment extends usable life. Actual shelf life depends on the batch, the salt form, and the container.
It normally reports the share of the chromatographic signal that belongs to the main peak, not a measure of activity. A high figure means few related substances were detected under the stated method and wavelength. Different laboratories and methods can return different values for the same material.
Retention time alone is weak evidence, because unrelated peptides can elute at similar positions. Amino acid analysis or peptide mapping gives stronger sequence information when a mass spectrometer is unavailable. Most laboratories still treat mass confirmation as the standard step for verifying the correct compound.
It is a synthetic peptide built from fifteen amino acids, with a mass of roughly 1419 daltons. The sequence is reported to match a fragment of a protein present in human gastric juice. It is not a naturally circulating hormone.